The site director at GlaxoSmithKline’s Montrose site says the multi-million pound investment the pharmaceutical company is making into the plant is a reflection on its staff.
GlaxoSmithKline (GSK) yesterday pledged £110 million to its Montrose site, as part of a £275 million investment into three of its UK sites.
The plant on Cobden Street, which employs more than 450 people, will receive almost a third of the funding.
Barnard Castle in County Durham will receive £92M and Ware in Hertfordshire will get £74M.
Les Thomson, site director at Montrose, confirmed a new, state-of-the-art facility to manufacture respiratory active ingredients is to be built.
He said: “The investment of £110M at Montrose is fantastic news for the site, the staff and the local community.
“We have seen significant investment over the last four years and this news allows us to continue the development of this great and long standing facility.
“The commitment shown by GSK is a reflection of the quality and dedication of the people we have here and the strong compliance culture that exists at Montrose as we look to further create world-class manufacturing capability.”
The new facility at Montrose is to replace an existing building that has manufactured respiratory active ingredients on the site for more than 40 years.
A number of jobs will be created during the estimated three-year construction phase.
The new facility will provide long-term security for the existing manufacturing related roles and will ensure a continued supply of respiratory medicine to millions of patients around the world.
Montrose Councillors David May and Bill Duff welcomed the news of the investment.
Mr May said: “It is great news for Montrose, as well as Angus, that GSK has announced that £110M will provide a new, state-of-the-art facility for the manufacture of respiratory active ingredients in its site in the town.
“This development will not only help to support the 450 jobs in their Montrose complex but it is hoped that it will also create new jobs and be a real boost to the local economy and provide real assurance to many people and their families.
“This investment it a real tribute and testament to the skills of the GSK Montrose staff and once more shows their role in advanced manufacturing in life sciences.”
Mr Duff said: “I was delighted to hear the great news this week about the £110 Million investment in GSK’s Montrose plant.
“This is good news both for Montrose and the whole of Angus and, of course, the workforce where it secures many skilled jobs.
“It is also a boost to many local Angus firms that work for GSK and can expect spin offs from this project.
“It’s a long way for since that grim day in 2004 when closure of GSK was announced and the turn round is testament to the hard work and well earned reputation of the Montrose GSK staff.”